13D Filing: JFL Capital Management and Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
...... (read more)
Merrimack Pharmaceuticals Inc (MACK)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Newtyn Management Noah Levy And Eugene Dozortsev | 1,144,583 | $7,955 | +29% | 1.5% |
| 2. | Clearline Capital Marc Majzner | 0 | $0 | 0% | |
| 3. | D E Shaw D. E. Shaw | 106,643 | $741 | +94% | 0% |
| 4. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.00 | 16,200 | Large Shareholder, Other | 1,241,896 | 2019-04-17 | Filing | |
| $5.95 | 20,450 | Large Shareholder, Other | 1,225,696 | 2019-04-16 | Filing | |
| $5.73 | 30,110 | Large Shareholder, Other | 1,205,246 | 2019-04-15 | Filing | |
| $5.81 | 32,873 | Large Shareholder, Other | 1,175,136 | 2019-04-08 | Filing | |
| $6.12 | 50,000 | Large Shareholder, Other | 1,142,263 | 2019-04-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.23 | 7,796 | Director | 22,681 | 2017-09-15 | Filing | |
| $14.20 | 100 | Director | 22,681 | 2017-09-14 | Filing | |
| $14.27 | 6,800 | Director | 22,681 | 2017-09-13 | Filing | |
| $14.46 | 14,756 | Director | 22,681 | 2017-09-11 | Filing | |
| $3.72 | 4,097 | Officer | 101,731 | 2017-05-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,092,263 | $7,591 | 5.28% | |
| 2. | 425,359 | $2,956 | 2.62% | |
| 3. | 216,118 | $1,502 | 0.63% | |
| 4. | 66,934 | $465 | 0.13% | |
| 5. | 4,200 | $186 | 0.1% |
News See All
Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde. The deal is worth close to $1.025 billion, with Onivyde...... (read more)
Is Merrimack Pharmaceuticals Inc (MACK) A Good Stock To Buy?
Looking for high-potential stocks? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock...... (read more)
5 Stocks Hedge Funds Hate The Most
Insider Monkey keeps a keen eye on the activity of the top hedge funds in the world, as our research has shown that hedge funds’ long positions can deliver market-beating returns. Likewise, we also...... (read more)
Merrimack Pharmaceuticals Inc (MACK) Sees Earnings Boost As FDA Accepts Application For Generic Drug
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have moved closer to introducing their generic version of Johnson & Johnson (NYSE:JNJ) drug DOXIL...... (read more)
Here’s Why TASER International, Heron Therapeutics and Three Other Stocks Are Trading Lower on Monday
The markets have opened the fourth quarter on a negative note. While there are uncertainties on account of upcoming presidential election and deteriorating financial market health in Germany, the US...... (read more)
What Is Going On With These Falling Stocks?
After opening flat and falling into the red, the broader markets are now in the green this afternoon as investors weigh the overall positive start to earnings season. Among the shares that haven't rallied...... (read more)
Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)?
Hedge funds are not perfect. They have their bad picks just like everyone else. Micron, a stock hedge funds have loved, lost 50% during the last 12 months ending in October 30. Although hedge funds are...... (read more)
Hedge Funds Have This To Say About Tuesday’s Healthcare Flops
Tuesday was a bad day for three healthcare stocks in particular. Shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Inovio Pharmaceuticals Inc (NASDAQ:INO), and Second Sight Medical Products Inc (...... (read more)
Should You Buy Merrimack Pharmaceuticals Inc (MACK) After The 10% Surge?
Should you buy Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock today? The firm’s share price surged 10.22% on June 18 to attain a closing price of $12.19 after a heavy volume day. The stock has had...... (read more)
Billionaire Hedge Funds
